Renal Biomarkers Market By Product (Functional Biomarkers, Injury Biomarkers, Prognostic and Multivariable Biomarker Tests); By Application (Chronic Kidney Disease Screening and Diagnosis, Kidney Function Monitoring, Acute Kidney Injury Risk Assessment, Disease Progression Risk Assessment, Dialysis and Transplant Monitoring, Drug Development and Nephrotoxicity Assessment); By End User (Hospitals, Diagnostic and Reference Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Dialysis Centres, Transplant Centres); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation and Forecast, 2026–2032

Renal Biomarkers Market: Earlier Kidney-Risk Detection Expands Specialized Testing

The Global Renal Biomarkers Market was valued at USD 1.35 billion in 2025 and is projected to reach USD 2.40 billion by 2032, growing at a CAGR of 8.6%, according to Strategic Market Research.

 

The renal biomarkers market comprises routine kidney function tests and confirmatory filtration assays. It also encompasses acute kidney injury risk tests, prognostic algorithms, and biomarkers used in pharmaceutical safety studies. Purchasing and utilization differ by category. Routine demand is measured through completed laboratory reports with eGFR or urine albumin-to-creatinine ratio results. Specialty demand is tracked through completed assays, cartridges, or algorithmic reports.

 

Creatinine and urine albumin account for most testing activity because primary care practices, diabetes clinics, hospitals, nephrology departments, dialysis centres, and transplant programs use them repeatedly. Cystatin C, NGAL, KIM-1, TIMP-2, IGFBP7, and multivariable tests command higher revenue per result by supporting specific decisions involving filtration accuracy, imminent kidney injury, progression risk, or drug toxicity. Exact global unit volumes remain unavailable because creatinine is frequently bundled into metabolic panels and hospitalized patients may receive several tests during one episode.

 

Kidney Disease Creates a Large but Underdiagnosed Testing Population

The Global Burden of Disease analysis estimated that 788 million adults aged 20 years or older were living with chronic kidney disease in 2023, with an age-standardized prevalence of 14.2%. WHO reports a lower estimate of 674 million because the two sources use different disease definitions and modelling methods. Both estimates identify CKD as one of the largest disease populations addressed through laboratory testing.

The CDC estimates that 37 million U.S. adults have CKD stages 1–4 and that approximately 87% are unaware of their condition. Most undiagnosed patients enter testing pathways through diabetes, hypertension, cardiovascular disease, older-adult care, or an incidental abnormal chemistry result rather than through kidney-specific symptoms.

Diabetes and hypertension expand the testing population beyond patients already diagnosed with CKD. In 2024, 589 million adults aged 20–79 were living with diabetes globally, including 252 million who remained undiagnosed. WHO estimated that 1.4 billion adults aged 30–79 had hypertension during the same year. These populations overlap and cannot be added, but both conditions increase the number of patients considered for eGFR and uACR assessment.

Kidney failure involves fewer patients but much more frequent monitoring. The U.S. Renal Data System reported 831,192 people receiving treatment for end-stage renal disease at the end of 2023. A global analysis estimated that 4.59 million people were receiving kidney replacement therapy. Dialysis and transplant patients require repeated chemistry, filtration, electrolyte, and protein measurements rather than a single diagnostic test.

 

Missed Albuminuria Testing Limits Routine CKD Detection

KDIGO recommends measuring both glomerular filtration and urine albumin in patients at risk of CKD. Creatinine-based eGFR assesses filtration, while uACR identifies glomerular damage and improves kidney and cardiovascular risk classification. Persistent abnormality over at least three months is generally required to establish CKD, creating repeat-test demand after an initial abnormal result.

A national U.S. laboratory analysis covering 28,295,982 patients with diabetes or hypertension found that 89.6% received eGFR testing at least once, while only 21.0% received uACR testing. Mean annual concordant testing was 13.1%, and more than 80% of patients did not receive both assessments during the study period.

Health systems can close part of this gap through combined kidney profiles, electronic order sets, urine-collection prompts, reflex rules, and clinician alerts. These measures increase utilization without requiring hospitals or laboratories to purchase a new diagnostic platform.

A separate U.S. electronic-health-record study showed that 11,525 of 33,629 tested high-risk adults had uACR ≥30 mg/g, yielding a 34.3% positivity rate. Clinicians had selectively tested higher-risk patients, so the result should not be applied to every adult with diabetes or hypertension.

Albuminuria results influence medication review, monitoring frequency, nephrology referral, and clinical-trial eligibility. The EHR study associated uACR testing with higher use of ACE inhibitors, angiotensin receptor blockers, and SGLT2 inhibitors, although its observational design could not prove that testing directly caused treatment initiation.

 

Cystatin C Gains Use Around High-Consequence Decisions

Creatinine remains the routine filtration marker, but muscle mass, age, diet, and severe illness can distort the relationship between serum creatinine and kidney function. Clinicians use cystatin C when a creatinine-based estimate may misclassify a patient or when greater precision could alter drug dosing, transplant evaluation, specialist referral, or treatment eligibility.

The 2021 combined creatinine–cystatin-C equation achieved P30 accuracy of approximately 90.5%–90.8% in cited validation populations, compared with 86.5%–87.2% for the creatinine-only equation. P30 measures the proportion of estimated results falling within 30% of directly measured GFR.

Roche, Siemens Healthineers, and Diazyme supply FDA-cleared cystatin-C assays that laboratories can run on established chemistry systems. Compatibility with installed analyzers lowers implementation costs and reduces staff training requirements. Reimbursement remains conditional in some U.S. jurisdictions, where laboratories may need to document why creatinine alone is insufficient.

 

AKI Assays Address the Delay Before Creatinine Rises

Serum creatinine may not rise until 24–72 hours after an acute kidney insult. NGAL can increase within approximately two to four hours, while TIMP-2 and IGFBP7 identify tubular cell-cycle arrest before a substantial decline in filtration becomes measurable. KIM-1, NAG, and L-FABP provide additional evidence of tubular injury, ischemic stress, or nephrotoxic damage.

NGAL meta-analyses report sensitivity ranging from 65% to 89% and specificity from 60% to 85%, depending on patient selection and clinical setting. Paediatric studies conducted around cardiopulmonary bypass have reported diagnostic AUC values as high as 0.94, but tightly controlled surgical cohorts do not represent general ICU or emergency populations.

Researchers selected the TIMP-2 × IGFBP7 combination through the 744-patient Sapphire study and evaluated its risk thresholds further in the 154-patient Opal study. A score of at least 0.3 supports sensitive identification of patients at elevated risk of moderate-to-severe AKI within 12 hours. A score above 2.0 identifies a narrower population with greater specificity.

bioMérieux commercializes NephroCheck for adults aged 21 years or older with recent cardiovascular or respiratory compromise in an ICU. The test calculates an AKIRisk score from urinary TIMP-2 and IGFBP7 and must be interpreted with standard clinical findings. FDA-reviewed studies reported high negative predictive values but lower positive predictive values, making the assay more useful for risk exclusion and structured surveillance than for confirming AKI independently.

BioPorto’s ProNephro AKI measures urinary NGAL in patients aged three months to under 22 years within specified ICU and transplant pathways. The test reported sensitivity of 72.3%, specificity of 86.3%, and a negative predictive value of 96.9% among 514 evaluable participants. Availability on Roche’s cobas c 501 platform reduces implementation requirements, although the current paediatric indication restricts the addressable U.S. population.

 

Prognostic Tests Prioritize Patients at Risk of Rapid Progression

KidneyIntelX.dkd combines plasma TNFR-1, TNFR-2, and KIM-1 with BUN, HbA1c, uACR, and clinical variables. The FDA granted De Novo authorization in June 2023 for assessing the risk of a sustained eGFR decline of at least 40% over up to five years in adults with type 2 diabetes and established CKD.

The authorization does not cover population screening, initial CKD diagnosis, serial treatment monitoring, or measurement of therapeutic response. Nephrologists and diabetes-care teams use the result to identify diagnosed patients who may require closer follow-up or more intensive management.

Renalytix reported FY2025 testing revenue of USD 2.7 million, Medicare reimbursement of USD 950 per reportable result, and more than 15,000 patients tested cumulatively. Utilization remains small compared with routine creatinine testing, but the reimbursement level demonstrates the pricing difference between a standard chemistry result and a multivariable progression-risk report.

 

Functional Biomarkers Retain Revenue Leadership

Functional biomarkers accounted for approximately 51.78% of renal biomarker revenue in 2025 because creatinine, BUN, cystatin C, and calculated eGFR are used across primary care, hospitals, dialysis, and reference laboratories. Upregulated injury proteins are forecast to expand at an 8.12% CAGR through 2031 as NGAL, KIM-1, TIMP-2, and IGFBP7 enter defined ICU, transplant, and drug-safety workflows. Functional markers will retain volume leadership, while injury markers generate more revenue per specialized result.

 

Automated Immunoassays Challenge ELISA-Based Workflows

ELISA generated approximately 46.10% of diagnostic-technique revenue in 2025 because research laboratories and clinical studies use it across established protein biomarkers and multi-analyte validation programs. Chemiluminescent immunoassays are projected to register an 8.2% CAGR through 2031 as laboratories transfer renal markers onto automated, high-throughput instruments. Hospitals favour assays that run on existing chemistry or immunoassay systems because they avoid separate analyzers, manual processing, and additional result-integration work.

 

Hospitals Remain the Main Purchasing Setting

Hospitals held approximately 53.70% of end-user revenue in 2025 because they perform repeated creatinine testing, AKI surveillance, transplant monitoring, critical-care assessment, and inpatient drug-dosing reviews. Academic and research institutes are forecast to expand at an 8.11% CAGR through 2031, supported by nephrotoxicity studies, biomarker qualification, translational kidney research, and clinical validation of multi-analyte panels. Reference laboratories remain important for cystatin C, kidney profiles, and externally ordered specialty tests.

 

North America Leads Commercial Adoption

North America accounted for approximately 41.80% of global revenue in 2025, supported by FDA-cleared AKI assays, Medicare reimbursement, large laboratory networks, and early adoption of prognostic testing. Asia-Pacific is forecast to expand at an 8.45% CAGR through 2031 as China and India manage the world’s largest national CKD populations. Regional growth will initially favour creatinine, eGFR, uACR, and automated immunoassays because laboratory access and affordability remain more influential than premium prognostic testing.

 

Pharmaceutical Developers Use Biomarkers to Detect Renal Toxicity Earlier

Pharmaceutical companies use KIM-1, NGAL, cystatin C, clusterin, NAG, and osteopontin to identify renal injury during preclinical research and selected clinical-development programs. Drug-safety studies generate fewer tests than routine diagnosis but require validated assays, longitudinal sample handling, central-laboratory consistency, and documentation suitable for regulatory review.

Chemotherapy agents, antibiotics, contrast agents, and experimental therapies with renal safety concerns create demand for biomarkers that identify tubular injury before serum creatinine rises. Suppliers must separate research-use, regulatory safety-biomarker, and patient-care claims because qualification in drug development does not automatically authorize an assay for routine clinical diagnosis.

 

Installed Platforms and Reimbursement Shape Competition

Roche supplies the Tina-quant Cystatin C Gen.2 assay and provides cobas platform access for BioPorto’s ProNephro AKI. Laboratories can add these tests without purchasing a dedicated kidney-testing instrument. Roche benefits where procurement teams favour broader assay menus, automated processing, consolidated maintenance, and long-term reagent contracts.

Siemens Healthineers competes through ADVIA cystatin-C assays and an established clinical-chemistry installed base. Laboratories can introduce confirmatory filtration testing while retaining existing instruments, quality controls, service arrangements, and reporting workflows. Adoption depends on physician ordering and reimbursement rather than analyzer availability alone.

bioMérieux acquired Astute Medical and incorporated NephroCheck into the VIDAS portfolio. The assay measures urinary TIMP-2 and IGFBP7 in a restricted adult ICU population. FDA-reviewed performance, automation on VIDAS 3, and a defined 12-hour risk window support adoption in hospitals that have established AKI-prevention protocols.

BioPorto’s ProNephro AKI targets paediatric and young-adult ICU patients at risk of developing or sustaining stage 2 or 3 AKI. Roche distribution and cobas compatibility reduce laboratory barriers. Growth depends on physician adoption within the current indication and on future evidence or regulatory expansion into larger adult populations.

Renalytix competes through KidneyIntelX.dkd, laboratory services, payer agreements, and electronic patient-identification tools. Medicare reimbursement of USD 950 per reportable result gives the company a premium pricing route unavailable to routine chemistry assays. Wider use depends on identifying eligible patients, obtaining physician orders, securing payer coverage, and connecting each risk category to a defined management plan.

Labcorp combines serum creatinine, eGFR, urine albumin, urine creatinine, and uACR into one kidney profile. Health systems can replace separate orders with a guideline-aligned panel and reduce missed albuminuria testing. Labcorp’s national laboratory data also quantify the utilization gap between widespread eGFR reporting and limited uACR completion.

 

Clinical Action Determines Whether New Tests Scale

Hospitals are unlikely to adopt a specialty renal biomarker solely because it detects injury earlier. NephroCheck and ProNephro require defined ICU populations, and their predictive values change with patient selection. Each result must connect to surveillance, medication review, fluid management, nephrology consultation, or another agreed intervention.

Cystatin C use depends on medical-necessity documentation and coverage in some payer settings. uACR completion depends on urine collection, repeat confirmation, and clinician follow-up. KidneyIntelX requires electronic identification of eligible patients, reimbursement, physician ordering, and a management pathway for low-, intermediate-, and high-risk results.

Health systems closing the eGFR–uACR testing gap will generate most near-term routine growth. Laboratories adding cystatin C will capture demand around dosing, transplant, and referral thresholds. Hospitals will adopt AKI assays selectively where critical-care teams have agreed on how to respond to the result. Injury and prognostic biomarkers will expand more broadly when clinical studies demonstrate changes in treatment decisions, resource use, or kidney outcomes.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.35 Billion
Revenue Forecast in 2032	USD 2.40 Billion
Overall Growth Rate	CAGR of 8.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Functional Biomarkers, Injury Biomarkers, Prognostic and Multivariable Biomarker Tests
Functional Biomarkers	Serum Creatinine, Blood Urea Nitrogen, Cystatin C, Urine Albumin
Injury Biomarkers	NGAL, KIM-1, TIMP-2, IGFBP7, NAG, L-FABP, Clusterin, Osteopontin
By Application	Chronic Kidney Disease Screening and Diagnosis, Kidney Function Monitoring, Acute Kidney Injury Risk Assessment, Disease Progression Risk Assessment, Dialysis and Transplant Monitoring, Drug Development and Nephrotoxicity Assessment
By End User	Hospitals, Diagnostic and Reference Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Dialysis Centres, Transplant Centres
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Germany, UK, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Mexico, GCC Countries, South Africa
Market Drivers	Rising prevalence of chronic kidney disease and acute kidney injury, growing demand for earlier renal damage detection, wider adoption of sensitive injury biomarkers and multivariable tests, increasing nephrotoxicity assessment in pharmaceutical development, expansion of dialysis and kidney transplant monitoring
Customization Option	Available upon request